28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Neuronal dysfunction and cognitive deterioration in Alzheimer's disease (AD) are likely caused by multiple pathophysiological factors. 5 key findings →
Participants: 132 Evidence: low
Full summary, score breakdown and related studies → Original source
Interpretation of axonal damage biomarker Neurofilament Light chain (NfL) concentrations is difficult due to the lack of age-specific and disease-specific reference values. 2 key findings →
Participants: 1,698 Evidence: low
Full summary, score breakdown and related studies → Original source
Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD) spectrum disorders and late-onset primary psychiatric disorders (PPD), diagnostic biomarkers reflecting the different underlying pathophysiologies are urgently needed. 3 key findings →
Participants: 91 Evidence: low
Full summary, score breakdown and related studies → Original source
There were significant global differences in Aβ1-42, T-tau, T-tau/Aβ1-42 ratio, P-tau-181, NFL, AβX-42, AβX-42/X-40 ratio, APPα, and APPβ between groups. 1 key finding →
Participants: 156 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. 2 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source
CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology. 1 key finding →
Participants: 221 Evidence: low
Full summary, score breakdown and related studies → Original source
To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results. 5 key findings →
Participants: 200 Evidence: low
Full summary, score breakdown and related studies → Original source
For MCI subjects, dyslipidemia may contribute to AD-related neurodegeneration while hypertension may contribute to vascular pathology. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The interaction between SORL1 polymorphisms and Aβ formation requires further study. 4 key findings →
Participants: 798 Evidence: low
Full summary, score breakdown and related studies → Original source
The presence of both APOE ε4 and MHT may be associated with elevated amyloid deposition and AD pathology in this sample of participants who demonstrated high familial AD risk. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings suggest that blood-based biomarkers of AD-related pathology predict cognitive decline in patients with cardiovascular diseases. 5 key findings →
Participants: 412 Evidence: low
Full summary, score breakdown and related studies → Original source
Presented results indicate the pivotal role of FABP3 and ApoE4 in AD pathology as lipid-related biomarkers, but studies on larger cohorts are needed. 3 key findings →
Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings suggest a relationship between bone health and cognitive health. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis, predict disease progression, stratify individuals and track response to candidate therapies in drug trials. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Blood-based biomarker assays of plasma β-amyloid (Aβ) and tau have the advantages of cost-effective and less invasive for the diagnosis of Alzheimer's disease (AD). 1 key finding →
Participants: 160 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Oligomeric forms of amyloid-β (Aβ), tau, and TDP-43 play important roles in Alzheimer's disease (AD), and therefore are promising biomarkers. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Loss-of-function mutation of triggering receptor expressed on myeloid cell 2 (TREM2) is associated with increased risks for Alzheimer's disease (AD). 3 key findings →
Participants: 129 Evidence: low
Full summary, score breakdown and related studies → Original source
N-glycosylation has been identified as a critical attribute maintaining the beneficial effects of autoreactive Aβ antibodies. 1 key finding →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
Using worldwide health data, researchers project that the number of people living with dementia will nearly triple by 2050, from about 57 million in 2019 to about 153 million. 4 key findings →
Design: modelling Evidence: high
Full summary, score breakdown and related studies → Original source
This German study challenged the common assumption that keeping a person with dementia at home is always cheaper than nursing home care. 4 key findings →
Design: cross-sectional Participants: 176 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among nursing home residents with dementia, discontinuing long-term antipsychotic medication use was associated with lower risks of hospitalization, pneumonia, and urinary tract infections, suggesting clinical benefits in this population. 4 key findings →
Design: cohort Participants: 4,222 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Although ACP programs in nursing homes may increase DNR directives, evidence of other EoL outcomes remains limited and inconsistent. 5 key findings →
Design: meta-analysis Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Increasing oily fish intake has been proposed as a strategy for Alzheimer's disease (AD) prevention, but evidence for long-term benefit remains limited. 2 key findings →
Design: cohort Participants: 2,012 Evidence: null result
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Relationship between alcohol drinking and incident dementia remained uncertain. 2 key findings →
Design: cohort Participants: 296,715 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →